
CAS:183133-96-2
Molecular formula:C45H57NO14
Molecular weight:835.93
Product description:Cabazitaxel is a semi-synthetic derivative of a natural taxoid. It was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.



